MED'INN'Pharma
Description
MIP developed a tech platform allowing production of biolocal drugs 100% human origin, secretome-based. We have 2 clinical-ready candidates addressing unmeet needs in scleroderma and biologic-resistant rheumatoid arthirtis. we are planning a serie A in the coming months to cover mainly the clinical developement of one candidate.